Segments - Drug Delivery Pumps Market by Type (Insulin Pumps, Volumetric Pumps, Enteral Pumps, Syringe Pumps, Ambulatory Pumps, and Others), Application (Diabetes, Pediatrics, Oncology, Gastroenterology, and Others), End-user (Hospitals, Home Care Settings, and Clinics), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
The global drug delivery pumps market size was USD XX Billion in 2022 and is likely to reach USD XX Billion by 2031, expanding at a CAGR of XX% during 2023–2031. The market is driven by the increasing prevalence of chronic diseases across the globe.
Rising demand for ambulatory drug delivery pumps and an increasing geriatric population are expected to boost the market during the assessment period. With the advancement in medical technology and the emergence of several developing economies, there has been a significant expansion in the number of hospitals. This is leading to a large number of surgical procedures incorporating drug delivery pumps during surgery and post-operation care. Owing to these factors, the market is projected to grow substantially in the coming years.
As per the survey report published in August 2023, the global market value of surgical procedures conducted in 2022 is more than USD 3 trillion. The value is estimated to rise to USD 6 trillion by the end of 2030.
Drug delivery pumps are highly useful to patients, as they easily deliver medications such as hormones, antibiotics, pain relievers, chemotherapy drugs, and nutrients. Thus, it helps to decrease the medication. Furthermore, the use of drug delivery pumps has increased significantly in recent years as they can be controlled remotely. The rising adoption of these pumps for homecare and ambulatory services is likely to propel the market.
The research report finds that the COVID-19 pandemic boosted the drug delivery pumps market, due to the intensive use of fusion pumps across all medical facilities to deliver drugs to patients. These pumps helped patients with preset doses of anti-viral medicines at fixed intervals of time. The increased rate of patient admissions to the hospital led to a high demand for drug-delivery pumps during this period.
Artificial intelligence (AI) is anticipated to provide significant propulsion to the drug delivery pumps market. AI aids in the analysis of complex associations between formulation components, drug properties, and physiological influences to calculate the drug impact at each scale. Furthermore, it reduces the probability of human error and augments patient care.
Growing occurrence of chronic diseases is expected to drive the market during the projection period. The unhealthy habits associated with the modern lifestyle have increased health issues among people globally. A sedentary lifestyle affects overall health and impedes the sustainability and functioning of the human body. This is giving rise to chronic diseases such as diabetes and cancer. As a result, there is a need for regularized medication for such people, which raises the requirement for drug delivery pumps, thereby propelling the market. For Instance,
Increasing use of ambulatory services is projected to boost the market during the assessment period. These services supply analgesics, total parental infusion (TPN), and chemotherapy drugs through ambulatory infusion pumps (AIP), which are small battery-operated pumps that slowly deliver the medicine. With the general focus shifting from hospitals to ambulatory centers, there is expected to be a high demand for drug delivery pumps by these services.
Strict regulations for the production and incorporation of drug delivery pumps are likely to hamper the market during the forecast period. The organizations have stringent parameters to ensure the quality of drug delivery pumps, making them not prone to error, as the wrong dosage to the patients can be lethal. The regulations and quality standards cause a significant number of product recalls to remove faulty products from the market. Such instances are likely to restrain the market during the assessment period.
High adoption of drug delivery pumps in developing nations is anticipated to provide substantial growth opportunities for the market. Several emerging economies such as India, China, and Brazil are taking substantial research and development initiatives for the development of innovative medical technologies. Furthermore, factors such as infrastructural development of healthcare facilities and cost-effective manufacturing have increased the implementation of modern equipment and instruments in medical practices. This is expected to create favorable conditions for the market expansion.
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Drug Delivery Pumps Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Type (Insulin Pumps, Volumetric Pumps, Enteral Pumps, Syringe Pumps, Ambulatory Pumps, and Others), Application (Diabetes, Pediatrics, Oncology, Gastroenterology, and Others), and End-user (Hospitals, Home Care Settings, and Clinics) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
3M; B. Braun SE; Baxter; BD (Becton Dickinson); DaVita Inc.; Diaverum Deutschland Gmbh.; Medtronic; Fresenius SE & Co. KGaA; Nikkiso Co., Ltd; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; and NIPRO. |
Based on type, the drug delivery pumps market is divided into insulin pumps, volumetric pumps, enteral pumps, syringe pumps, ambulatory pumps, and others. The insulin pumps segment is projected to hold the major share of the market during the projection period, owing to the increasing cases of insulin resistance among people. The insulin pumps deliver bolus doses post meals, as well as have the ability to provide constant basal insulin doses.
Insulin delivery pumps help maintain tight glycemic control, offering accuracy, flexibility, and improved quality of life. With the rise in cases of obesity and diabetes, this segment is expected to have substantial growth during the projection period.
On the basis of application, the global market is segregated into diabetes, pediatrics, oncology, gastroenterology, and others. The diabetes segment is projected to expand at a significant CAGR during the forecast period, due to the rising sedentary lifestyle and obesity. These habits have increased the global prevalence of diabetes.
Diabetes is the source of a wide range of medical problems including chronic kidney disease (CKD), heart disease, nerve damage in the limb extremities, and affected mental health. There is a large demand for insulin pumps among patients to avoid these issues, which is likely to boost this segment during the forecast period.
As per the report by National Diabetes Statistics, published by the Center for Disease Control and Prevention (CDC) in 2022, approximately 37.3 million individuals in the US (11.3% of the entire population in the nation) have diabetes. Out of this, close to 28.7 million individuals have confirmed diagnoses of diabetes, while 8.5 million cases are undiagnosed.
The pediatrics segment is projected to register a considerable CAGR during the forecast period, due to the increasing number of births worldwide. This has led to a rise in demand for intravenous infusion pumps, which are used extensively in medical procedures to deliver fluids at a precise and customizable rate. This is likely to propel the segment during the assessment period.
On the basis of end-user, the drug delivery pumps market is segmented into hospitals, home care settings, and clinics. The hospitals segment is anticipated to register a robust growth rate during the forecast period, due to hospitals’ procuring capacity of modern and costliest drug delivery devices.
A huge flow of patients visiting these facilities, and the availability of trained medical professionals who operate the pump has increased the adoption of drug delivery pumps in this segment. In addition, the initiatives by various governments to reduce the cost related to prolonged hospitalization and related services are expected to boost the market in the coming years.
In terms of region, the global drug delivery pumps market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, due to the growing occurrence of chronic diseases. In addition, a large number of surgeries and intensive research & development activities in the field of medical science have led to the implementation of advanced technology in the development of drug delivery pumps, which is projected to propel the market in this segment.
Asia Pacific is likely to witness significant propulsion during the projected period, owing to the presence of several developing economies in this region, such as India and China. These countries are densely populated and have a high prevalence of chronic diseases such as cardiovascular illnesses, cancer, and diabetes. This is increasing the adoption of various drug delivery pumps, such as insulin pumps and infusion pumps, which are likely to propel substantial growth of the market in the region in the coming years.
The drug delivery pumps market has been segmented on the basis of
Key players competing in the global drug delivery pumps market are 3M; B. Braun SE; Baxter; BD (Becton Dickinson); DaVita Inc.; Diaverum Deutschland Gmbh.; Medtronic; Fresenius SE & Co. KGaA; Nikkiso Co., Ltd; Shenzhen Mindray Bio-Medical Electronics Co., Ltd.; and NIPRO.
These companies implement development strategies including mergers, partnerships, collaboration, product launches, acquisitions, and production expansion to expand their consumer base worldwide. They make intensive investments in research and development for the innovation of new products, which helps them stay ahead of the curve. For instance,
In April 2021, Medtronic, a worldwide leader in medical technology, launched the Medtronic Extended infusion set for some European countries. This infusion set is one of a kind and can be worn for up to seven days. Ideally, an infusion set delivers insulin through the pump to the body and needs to be replaced every few days interval.
In February 2021, Mindray, a global leader in innovative healthcare technology, released a ground-breaking infusion system, BeneFusion e Series. It is highly effective in the healthcare sector and comprises three models, eSP, eDS, and eVP. They offer enhanced workflow, safety, application, and informatics efficiency.